THERAPY DOSSIER · th-f155779c3cd7

PMX205

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28173736 ↗2017Reported benefit

The Alternative Receptor for Complement Component 5a, C5aR2, Conveys Neuroprotection in Traumatic Spinal Cord Injury

MouseSpinal cord injuryContusionC57BL/6 wild-type and C5ar2 knockoutFemale (from MeSH indexing)Acute treatment after spinal cord injury; exact start time and duration not sta…

Model: Contusive spinal cord injury in wild-type and C5ar2 knockout mice

Loss of C5aR2 lowered acute intraparenchymal TNF-alpha and IL-6 but worsened outcome, with larger lesion volumes, reduced myelin sparing and poorer functional recovery than wild-type controls, without changes in leukocyte mobilisation or neutrophil recruitment. Acute treatment with the C5aR1 antago…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…